Clinical Perspectives: Firstline Treatment Landscape in Higher-Risk MF

Panelists discuss how frequently patients with newly diagnosed myelofibrosis present with moderate or severe thrombocytopenia or both anemia and thrombocytopenia. They discuss how these factors and other disease characteristics like spleen size and constitutional symptoms influence their treatment approach and selection of JAK inhibitors.

Now Viewing

EP: 1.Clinical Perspectives: Firstline Treatment Landscape in Higher-Risk MF

1. Dr Kuykendall to Dr Konala: How many of your patients with newly diagnosed myelofibrosis (MF) present with moderate thrombocytopenia: platelet count 50 to 100; vs severe thrombocytopenia: platelet count less than 50; vs both anemia and thrombocytopenia. 
2. Dr Kuykendall to Dr Konala: What is your general treatment approach for those with higher-risk MF? How does a patient’s baseline platelet count influence or impact your selection among the JAK inhibitor therapies? 
3. Dr Kuykendall: Please comment on any similarities and/or differences in your clinical practice. Please also comment on how you factor in other patient and/or other disease factors (eg, anemia, spleen size, constitutional symptoms).